Literature DB >> 3873405

Secretion of idiotypic IgM by the mouse B-cell leukaemia (BCL1) occurs spontaneously in vitro and in vivo.

A L Tutt, F K Stevenson, S Slavin, G T Stevenson.   

Abstract

An analysis has been carried out to investigate the ability of neoplastic cells from the mouse B-cell leukaemia (BCL1) to secrete idiotypic IgM. Tumour cells taken from the spleen and placed in short-term culture without stimulation secreted quite large amounts of idiotypic IgM with a mean value for six animals +/- SD of 11,5000 +/- 6800 molecules of pentamer/cell/hr, with levels increasing steadily over a 7-hr period. Tumour cells from the blood of matched animals also secreted idiotypic IgM in amounts generally less than the spleen cells (4100 +/- 2000 molecules/cell/hr. The IgM produced was found to be mainly pentameric, with some material of lower molecular weight. This idiotypic IgM could also be detected in the serum of leukaemic animals as pentameric IgM, and amounts increased during tumour development to 1-2 mg/ml in the terminal phase of disease. Since binding of anti-idiotypic antibody to tumour cells is inhibited by this material, it should be taken into account in immunotherapeutic schedules involving such antibody. However, it also presents a useful marker of disease, and perhaps of response to therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873405      PMCID: PMC1453581     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  11 in total

Review 1.  BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumor.

Authors:  K A Krolick; P C Isakson; J W Uhr; E S Vitetta
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  Spontaneous murine B-cell leukaemia.

Authors:  S Slavin; S Strober
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

Review 3.  Treatment of lymphoid tumors with anti-idiotype antibodies.

Authors:  G T Stevenson; F K Stevenson
Journal:  Springer Semin Immunopathol       Date:  1983

Review 4.  Neoplastic B cells as targets for antibody-ricin A chain immunotoxins.

Authors:  E S Vitetta; K A Krolick; J W Uhr
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

5.  Antibodies against urinary light chain idiotypes as agents for detection and destruction of human neoplastic B lymphocytes.

Authors:  A L Tutt; F K Stevenson; J L Smith; G T Stevenson
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

6.  Lymphokine-induced IgM secretion by clones of neoplastic B cells.

Authors:  K Brooks; D Yuan; J W Uhr; P H Krammer; E S Vitetta
Journal:  Nature       Date:  1983-04-28       Impact factor: 49.962

7.  Immunoglobulin produced by guinea-pig leukaemic B lymphocytes: its source and use as a monitor of tumour load.

Authors:  F K Stevenson; D Morris; G T Stevenson
Journal:  Immunology       Date:  1980-10       Impact factor: 7.397

8.  Acquisition of cell surface IgD after in vitro culture of neoplastic B cells from the murine tumor BCL1.

Authors:  P C Isakson; J W Uhr; K A Krolick; F Finkelman; E S Vitetta
Journal:  J Exp Med       Date:  1980-03-01       Impact factor: 14.307

9.  Extracellular idiotypic immunoglobulin arising from human leukemic B lymphocytes.

Authors:  F K Stevenson; T J Hamblin; G T Stevenson; A L Tutt
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

10.  Secretion of immunoglobulin by neoplastic B lymphocytes from lymph nodes of patients with lymphoma.

Authors:  F K Stevenson; E O Gregg; J L Smith; G T Stevenson
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

View more
  2 in total

1.  Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule.

Authors:  S Morecki; S Levi; Y Puyesky; S Slavin
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

2.  Characterisation of a new murine B cell lymphoma.

Authors:  L M Cobb; M J Glennie; H M McBride; G Breckon; T C Richardson
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.